Employment has begun of digital health unit engineers.
But biotech still has several hurdles to clear – including Roche’s rival.
For the first time, FDA approves drug on the basis of biomarkers, rather than location.
Italian pharma gets EU rights to Seloken.
Kite, Juno, and BlueBird will give updates on T-cell therapies.
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Early warning system should be introduced, says Economist Intelligence Unit.